echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Researchers design a highly selective RIPK1 inhibitor with a dual mode of action of "alternative + competition"

    Researchers design a highly selective RIPK1 inhibitor with a dual mode of action of "alternative + competition"

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Necroptosis is a controlled method of cell necrosis.


    The research team of Zhou Bing, Tang Wei, and Xu Yechun, researchers at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, started with the RIPK1 allosteric inhibitor GSK2982772 in clinical phase II, and carried out structure-based research based on the characteristics of the binding mode of the small molecule and the target protein.


    In summary, studies have revealed a class of highly active and selective RIPK1 inhibitors with a novel mode of action, which is expected to provide new strategies for the treatment of systemic inflammatory diseases and neurological diseases


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.